Key result
Lenvatinib therapy for thyroid cancer was associated with the development of posterior reversible encephalopathy syndrome and concomitant Takotsubo cardiomyopathy in a single patient case.
Case Report (n=1)
Lenvatinib therapy for thyroid cancer can be associated with severe adverse effects including posterior reversible encephalopathy syndrome and Takotsubo cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to PRES-takotsubo overlap; leaves open whether causal or coincidental.
// Young Kwang Chae 1, 2, * , Lauren Chiec 1, * , Scott K. Adney 1 , Josh Waitzman 1 , Ricardo Costa 3 , Benedito Carneiro 4 , Maria Matsangou 1, 2 , Mark Agulnik 1, 2 , Peter Kopp 1 and Frank Giles 1, 2 1 Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA 2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA 3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA 4 Lifespan Cancer Institute, Providence, RI 02906, USA * These authors are contributed equally to this work Correspondence to: Young Kwang Chae, email: young.chae@northwestern.edu Keywords: lenvatinib; posterior reversible encephalopathy syndrome; takotsubo cardiomyopathy; thyroid cancer Received: March 20, 2018 Accepted: May 19, 2018 Published: June 15, 2018 ABSTRACT As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potentially fatal side effects associated with these drugs to further determine risk factors for their development. The review presents a case of posterior reversible encephalopathy syndrome with concomitant Takotsubo cardiomyopathy, associated with use of lenvatinib therapy for thyroid cancer. It discusses the interventions performed and outcome. Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development.
No takes yet. Share an insight, caveat, or question.
Chae et al. (2018) conducted a case report in Thyroid cancer (n=1). Lenvatinib was evaluated on Development of posterior reversible encephalopathy syndrome and Takotsubo cardiomyopathy. Lenvatinib therapy for thyroid cancer was associated with the development of posterior reversible encephalopathy syndrome and concomitant Takotsubo cardiomyopathy in a single patient case.
Synapse has enriched 10 related papers. Consider them for comparative context: